- Home
- LSB vs LGVN Comparison
LSB vs LGVN Comparison
Compare LSB & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- LGVN
- Stock Information
- Founded
- LSB 2002
- LGVN 2014
- Country
- LSB China
- LGVN United States
- Employees
- LSB N/A
- LGVN N/A
- Industry
- LSB
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LSB
- LGVN Health Care
- Exchange
- LSB NYSE
- LGVN Nasdaq
- Market Cap
- LSB 22.3M
- LGVN 23.4M
- IPO Year
- LSB N/A
- LGVN 2021
- Fundamental
- Price
- LSB $1.00
- LGVN $1.31
- Analyst Decision
- LSB
- LGVN Strong Buy
- Analyst Count
- LSB 0
- LGVN 3
- Target Price
- LSB N/A
- LGVN $8.67
- AVG Volume (30 Days)
- LSB 24.2K
- LGVN 146.0K
- Earning Date
- LSB 07-07-2025
- LGVN 08-13-2025
- Dividend Yield
- LSB N/A
- LGVN N/A
- EPS Growth
- LSB N/A
- LGVN N/A
- EPS
- LSB N/A
- LGVN N/A
- Revenue
- LSB $79,415,311.00
- LGVN $2,225,000.00
- Revenue This Year
- LSB $39.33
- LGVN N/A
- Revenue Next Year
- LSB $75.61
- LGVN $51.48
- P/E Ratio
- LSB N/A
- LGVN N/A
- Revenue Growth
- LSB N/A
- LGVN 127.50
- 52 Week Low
- LSB $0.36
- LGVN $1.14
- 52 Week High
- LSB $6.82
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- LSB 37.29
- LGVN 50.13
- Support Level
- LSB $0.91
- LGVN $1.15
- Resistance Level
- LSB $1.03
- LGVN $1.32
- Average True Range (ATR)
- LSB 0.06
- LGVN 0.09
- MACD
- LSB 0.01
- LGVN 0.01
- Stochastic Oscillator
- LSB 43.75
- LGVN 45.31
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.